INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
39 hedge funds and large institutions have $84.6M invested in Inozyme Pharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Holders
39
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$1.3M | |
| 2 | +$449K | |
| 3 | +$134K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$123K |
| 5 |
Renaissance Technologies
New York
|
+$99.3K |
Top Sellers
| 1 | -$1.62M | |
| 2 | -$510K | |
| 3 | -$122K | |
| 4 |
CA
CHI Advisors
New York
|
-$101K |
| 5 |
Goldman Sachs
New York
|
-$60K |